Lanean...
Clinical Trials of Repurposed Antivirals for SARS-CoV-2
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has prompted the repurposing of drugs on the basis of promising in vitro and therapeutic results with other human coronavirus diseases, such as severe acute respiratory syndrome...
Gorde:
| Argitaratua izan da: | Antimicrob Agents Chemother |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society for Microbiology
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7449177/ https://ncbi.nlm.nih.gov/pubmed/32631826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01101-20 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|